Alzamend Neuro, Inc.
ALZN · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $6 | $7 | $5 |
| G&A Expenses | $0 | $3 | $7 | $7 |
| SG&A Expenses | $3 | $3 | $7 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $1 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $10 | $15 | $12 |
| Operating Income | -$4 | -$10 | -$15 | -$12 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$5 | -$10 | -$15 | -$12 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$10 | -$15 | -$12 |
| % Margin | – | – | – | – |
| EPS | -11.32 | -14.72 | -2.25 | -20.92 |
| % Growth | 23.1% | -554.2% | 89.2% | – |
| EPS Diluted | -11.32 | -14.7 | -2.25 | -2.1 |
| Weighted Avg Shares Out | 0 | 3 | 3 | 3 |
| Weighted Avg Shares Out Dil | 0 | 3 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$10 | -$15 | -$12 |
| % Margin | – | – | – | – |